Microbiome testing company Tiny Health clinches $33M to scale research, enterprise partnerships
Tiny Health, a microbiome testing company, has secured $33 million in a series B funding round led by Capital B, signaling growing investor confidence in the growing field of gut microbiome research and its potential applications in precision medicine. The capital will be used to advance research, expand provider education, scale the B2B platform, and grow the patient-facing AI agent. This move comes as the company launches a $5 million Microbiome Research Program to enable researchers, clinicians, and scientific partners to investigate intervention strategies in microbiome health.
Original reporting · fiercehealthcare.com
Read “Microbiome testing company Tiny Health clinches $33M to scale research, enterprise…” at Fierce Healthcare →How this was written. Awesome B2B wrote this article with a language model from Fierce Healthcare’s reporting (model: @cf/ibm-granite/granite-4.0-h-micro); it describes that reporting rather than adding to it. The original, linked above, is the full story.
Key points from Fierce Healthcare’s report
- Tiny Health raised $33 million in an oversubscribed series B round, bringing its total raised capital to $46 million, to advance research, expand provider education, scale the B2B platform, and grow the patient-facing AI agent.
- The company has over 6,000 practitioners on its platform and 47 enterprise partners, with its B2B platform growing 4x last year.
- Tiny Health launched a $5 million Microbiome Research Program to enable researchers, clinicians, and scientific partners to investigate intervention strategies in microbiome health, aiming to help them add a microbiome layer to their existing work or plans using Tiny tests
From the source
Alongside the funding news, Tiny announced the launch of a $5 million Microbiome Research Program to enable researchers, clinicians and scientific partners to investigate important intervention strategies in microbiome health.